Venaxis kurz vor der FDA Zulassung
Seite 1 von 2 Neuester Beitrag: 25.04.21 01:39 | ||||
Eröffnet am: | 21.04.14 00:48 | von: usambara | Anzahl Beiträge: | 34 |
Neuester Beitrag: | 25.04.21 01:39 | von: Leahjssya | Leser gesamt: | 11.211 |
Forum: | Hot-Stocks | Leser heute: | 18 | |
Bewertet mit: | ||||
Seite: < | 2 > |
Ich denke schon denn die Insiderkäufe sprechen eine deutlich Sprache.
http://secfilings.nasdaq.com/...4&RcvdDate=4%2F17%2F2014&pdf=
ging der Kurs bereits bis auf 4$ und vieles deutet auf eine Zulassung hin.
http://ih.advfn.com/p.php?pid=nmona&article=62359377
à bientôt
OC
Noch dazu
http://ih.advfn.com/p.php?pid=nmona&article=62294037
à bientôt
OC
finde APPY ncht auf dem FDA Kalender und stehe noch aussen.
Hast Du noch eine heissen Tipp für die kommenden Wochen?
Grüße
Ich schaue mal nach
muss über Pfingsten arbeiten
Melde mich via BM
à bientôt
OC
à propos:Appy 31 Mars (90 Tag Dead line FDA...)Also Juni ? oder Juli ? Zulassung
Inovio Pharm schaue nach
Heute News...http://finance.yahoo.com/news/...iates-cervical-cancer-080000620.html
à bientôt
OC
http://www.prnewswire.com/news-releases/...venaxis-inc-300027869.html
A live audio webcast will be accessible via the Investor Relations section of the Venaxis website, www.venaxis.com/webcast/. Participants and investors may also access the conference call by dialing 1-888-455-2260 (U.S.) or 1-719-457-2645 (Toll - International).
A replay of the call will be available approximately an hour after the end of the conference call on the Company's website. To access the webcast, please visit the investor relations section of the Venaxis website at www.venaxis.com/webcast/.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low probability for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent, and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While the FDA clearance process and status is being evaluated, a limited commercial launch for the APPY1 Test is advancing in select European countries. For more information, visit www.venaxis.com.